ACTRN12608000474358招募中1 期
Phase 1B/II dose escalation study to assess the feasibility and tolerability of the combination of sunitinib with standard pre-operative radiotherapy for soft tissue sarcoma
Peter MacCallum Cancer Centre0 个研究点目标入组 26 人开始时间: 2008年9月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 16 Years 至 o limit（—）
- 性别
- All
入选标准
- •Histologically confirmed soft-tissue sarcoma suitable for neoadjuvant radiotherapy and surgery; minimum age 16 years; Eastern Cooperative Oncology Group (ECOG) performance status =1 or less; life expectancy of greater than 6 months; patients must have normal organ and marrow function; no evidence of a bleeding or thrombotic tendency, and no evidence of arterial or venous thrombosis; not pregnant or breastfeeding; and the ability to give written informed consent.
排除标准
- •Soft-tissue sarcoma located in sites where radiotherapy is associated with significant exposure of abdominal viscera; patients with other invasive malignancies, with the exception of non-melanoma skin cancer, in the last 5 years; patients receiving any other therapeutic investigational agents; patients who are receiving concurrent treatment with any other anti-cancer therapy; evidence of distant metastases; uncontrolled intercurrent illness; patients who are pregnant or breast feeding.
研究者
相似试验
进行中（未招募）
不适用
A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced MalignanciesAdvanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative chemotherapy.MedDRA version: 8.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2006-006515-76-GBOncolytics Biotech Inc
进行中（未招募）
1 期
A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemMedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2010-024069-30-GBAstraZeneca AB400
已完成
2 期
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus ErythematosusNL-OMON35833Astra Zeneca12
进行中（未招募）
不适用
A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemSystemic Lupus ErythematosusEUCTR2010-024069-30-BGAstraZeneca AB400
进行中（未招募）
不适用
A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemMedDRA version: 13.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2010-024069-30-ESAstraZeneca AB544